Artelo Biosciences Inc (ARTL) Dividend History

$1.47 $-0.02

Dividend Score
Dividend Yield
0%

Annual Payment
$0

Payout Ratio
0%
Dividend Increases
0 yrs

Price Chart

Key Metrics

Sector Healthcare
Industry Biotechnology
Avg daily volume 17,513
Market cap 4,647,890
Beta 1.19
Trailing 12 Month EPS -3.33
Next Earnings Date
Ex-dividend date
P/E ratio 0

Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Dividend Payments

Forward Yield
0%
Forward Payment
$0

Trailing Yield
0%
Trailing Payment
$0

Last Increase
> 10 Years Ago
Last Cut
> 10 Years Ago

5 Year Average Yield
0%
Vs Current Yield
0%

5 Year Div Growth Rate
0%
Payment Frequency
-

Historical Dividend Payments